BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1420 related articles for article (PubMed ID: 36587382)

  • 1. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
    Neagu MR; Reardon DA
    Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Neuro-Oncology.
    Majd N; Dasgupta P; de Groot J
    Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in immunotherapy for glioblastoma multiforme.
    Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
    Front Immunol; 2022; 13():944452. PubMed ID: 36311781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
    Wang C; Yu M; Zhang W
    Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Advances in Immunotherapy for Glioblastoma.
    Mende AL; Schulte JD; Okada H; Clarke JL
    Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Neuro-oncology.
    Majd NK; Dasgupta PR; de Groot JF
    Adv Exp Med Biol; 2021; 1342():233-258. PubMed ID: 34972967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
    Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
    J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.
    Maccari M; Baek C; Caccese M; Mandruzzato S; Fiorentino A; Internò V; Bosio A; Cerretti G; Padovan M; Idbaih A; Lombardi G
    Oncologist; 2024 Apr; 29(4):289-302. PubMed ID: 38048782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Checkpoint Inhibitors in Glioblastoma.
    Desai K; Hubben A; Ahluwalia M
    Target Oncol; 2019 Aug; 14(4):375-394. PubMed ID: 31290002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier.
    Frederico SC; Darling C; Bielanin JP; Dubinsky AC; Zhang X; Hadjipanayis CG; Kohanbash G
    Front Immunol; 2023; 14():1057567. PubMed ID: 36875096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?
    Quintarelli C; Camera A; Ciccone R; Alessi I; Del Bufalo F; Carai A; Del Baldo G; Mastronuzzi A; De Angelis B
    Front Immunol; 2021; 12():634031. PubMed ID: 34163465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Approaches for Immune Directed Treatment for Ovarian Cancer.
    Hardwick N; Frankel PH; Cristea M
    Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.